PMID: 32154900Mar 11, 2020Paper

Quality of life the goal of care for patients with ALS

Läkartidningen
Caroline IngreGert Staaf

Abstract

ALS is characterized by the degeneration of upper and lower motor neurons. In about 70% of patients with ALS the disease has an spinal onset, while about 30% of the patients have a bulbar onset.  Cognitive dysfunction and behavioral changes are seen in about 50% of the patients, and 15% develop frontotemporal dementia.  There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. The only disease modulating treatment approved for ALS in Sweden is Riluzole, sadly only with limited effect. Other treatments are symptomatic and the goal is to help patients achieve the best possible quality of life through multidiciplinary ALS teams.

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Related Papers

Nederlands tijdschrift voor geneeskunde
Michael A van EsLeonard H van den Berg
Current Opinion in Neurology
Philip Van Damme, Wim Robberecht
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Imen KacemRiadh Gouider
Rinshō shinkeigaku = Clinical neurology
H Mitsumoto, Wesley J Howe
Brain and nerve = Shinkei kenkyū no shinpo
H Mitsumoto
© 2021 Meta ULC. All rights reserved